Table 1

Reasons for premature discontinuation of the trial

Patient statusPlacebo (n (%))ASU-E (n (%))Total (n (%))
Randomised patients210 (100)189 (100)399 (100)
Completers127 (60.5)106 (56.1)233 (58.4)
Premature withdrawals83 (39.5)83 (43.9)166 (41.6)
 Inefficacy with total joint replacement36 (17.1)38 (20.1)74 (18.5)
 Inefficacy without total joint replacement9 (4.3)8 (4.2)17 (4.3)
 Adverse events11 (5.2)10 (5.3)21 (5.3)
 Consent withdrawal11 (5.2)17 (9.0)28 (7.0)
 Lost to follow-up8 (3.8)3 (1.6)11 (2.8)
 Other7 (3.3)6 (3.2)13 (3.3)
 Deaths1 (0.5)1 (0.5)2 (0.5)
  • ASU-E, avocado–soybean unsaponifiable—Expanscience.